◀ Back to EPHB2

EPHB2 — PRDX2

Text-mined interactions from Literome

Park et al., Int J Mol Med 2008 (Breast Neoplasms...) : TsA significantly increased the levels of ERK1/2 phosphorylation in MCF10A-ras cells
Yoshikawa et al., Eur J Pharmacol 2010 (MAP Kinase Signaling System) : Our results show, for the first time, that TSA inhibits TGF-beta1 induced ERK activation and overrides pro-apoptotic signals like Smad3 and p38 in human RPTECs
Zhang et al., Toxicon 2011 : Further investigation revealed that TSA can induce the activation of ERK1/2 in the three non-cancer cells but not in the cancer cells
Nunes et al., J Lipid Res 2012 : Chromatin immunoprecipitation analysis demonstrated that TSA induces the release of p-ERK1/2 from the CYP46A1 proximal promoter, whereas pretreatment with OA restores the co-occupancy of Sp3-ERK1/2 in the same promoter fragments
Yao et al., Life Sci 2012 (Stomach Neoplasms) : PD98059 enhanced TSA induced cell growth arrest, apoptosis and activation of p21 ( WAF1/CIP1 ), but reversed TSA induced activation of ERK1/2 and nuclear factor-?B ( NF-?B )
Shi et al., Biochem Biophys Res Commun 2013 : In parallel, hypoxia and TSA synergistically increased p-ERK and p-Akt without effecting VEGF-A level
Lu et al., PloS one 2013 : We determined that TSA increased basal ERK phosphorylation, and attenuated TZD mediated suppression of TNFa induced ERK phosphorylation, consistent with TSA 's effects on lipolysis ... These studies suggest that TSA , through down regulating PPAR?, attenuates TZD mediated suppression of TNFa induced ERK phosphorylation and lipolysis in adipocytes